Elucidation of the Controlled-Release Behavior of Metoprolol Succinate from Directly Compressed Xanthan Gum/Chitosan Polymers: Computational and Experimental Studies
Source abstract
Abstract
The development and evaluation of a controlled-release (CR) pharmaceutical solid dosage form comprising xanthan gum (XG), low molecular weight chitosan (LCS), and metoprolol succinate (MS) are reported. The research is, partly, based upon the utilization of computational tools: in this case, molecular dynamics simulations (MDs) and the response surface method (RSM) in order to underpin the design/prediction and to minimize the experimental work required to achieve the desired pharmaceutical outcomes. The capability of the system to control the release of MS was studied as a function of LCS (% w/w) and total polymer (LCS and xanthan gum (XG)) to drug ratio (P/D) at different tablet tensile strengths. MDs trajectories, obtained by using different ratios of XG/LCS as well as XG and high molecular weight chitosan (HCS), showed that the driving force for the interaction between XG and LCS is electrostatic in nature, the most favorable complex is formed when LCS is used at 15% (w/w) and, importantly, the interaction between XG and LCS is more favorable than that between XG and HCS. RSM outputs revealed that the release of the drug from the LCS/XG matrix is highly dependent on both the % LCS and the P/D ratio and that the required CR effect can be achieved when using weight fractions of LCS ≤ 20% and P/D ratios ≥2.6:1. Results obtained from in vitro drug release and swelling studies on the prepared tablets showed that using LCS at the weight fractions suggested by MDs and RSM data plays a major role in overcoming the high sensitivity of the controlled drug release effect of XG on ionic strength and pH changes of the dissolution media. In addition, it was found that polymer relaxation is the major contributor to the release of MS from LCS/XG tablets. Using Raman spectroscopy, MS was shown to be localized more in the core of the tablets at the initial stages of dissolution due to film formation between LCS and XG on the tablet surface, which prevents excess water penetration into the matrix. In the later stages of the dissolution process, the film starts to dissolve/erode, allowing full tablet hydration and a uniform drug distribution in the swollen tablet.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Polysaccharides Composition and Applications · Polysaccharides and Plant Cell Walls · Drug Solubulity and Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutical, Chemical & Environmental Science, Faculty of Engineering & Science, University of Greenwich, Medway Campus, Chatham Maritime, Kent ME4 4TB, United Kingdom
Department of Chemistry, The Hashemite University, P.O. Box 150459, Zarqa 13115, Jordan
Department of Chemistry, Isra University, Amman 11622, Jordan
Research and Innovation Centre, The Jordanian Pharmaceutical Manufacturing Company (PLC), P.O. Box 94, Naor 11710, Jordan
References (76)
Show source-provided references
1. Siegel R. A. · 2012 · 1910.1007/978-1-4614-0881-9_2 ↗
2. 10.1016/j.jconrel.2008.08.01210.1016/j.jconrel.2008.08.012 ↗
3. Pundir S. · Int. J. Drug Res. Technol. · 2013 · 3 · 12
4. Nokhodchi A. · Bioimpacts · 2012 · 2 · 175
5. Dadou S. M. · 2018 · 220
6. Lee P. I. · 2010 · 2110.1002/9780470640487.ch2 ↗
7. 10.1016/j.addr.2007.03.01210.1016/j.addr.2007.03.012 ↗
8. Racoviţǎ Ş. · Rev. Roum. Chim. · 2009 · 54 · 709
9. 10.1016/j.addr.2013.04.01610.1016/j.addr.2013.04.016 ↗
10. 10.3109/0363904930906299910.3109/03639049309062999 ↗
11. Benny I. S. · Int. J. PharmTech Res. · 2014 · 6 · 1322
12. Salyers A. A. · Appl. Environ. Microbiol. · 1977 · 33 · 31910.1128/aem.33.2.319-322.1977 ↗
13. 10.3109/0363904910904806310.3109/03639049109048063 ↗
14. 10.1016/0378-5173(94)00410-710.1016/0378-5173(94)00410-7 ↗
15. 10.1016/j.ijpharm.2005.01.01410.1016/j.ijpharm.2005.01.014 ↗
16. 10.1016/S0734-9750(00)00050-110.1016/S0734-9750(00)00050-1 ↗
17. 10.1016/j.carbpol.2011.04.06310.1016/j.carbpol.2011.04.063 ↗
18. 10.1002/app.4203510.1002/app.42035 ↗
19. 10.1016/j.carbpol.2012.10.06210.1016/j.carbpol.2012.10.062 ↗
20. 10.1016/j.ijpharm.2005.11.04210.1016/j.ijpharm.2005.11.042 ↗
21. 10.1106/XBFG-FYFX-9TW9-M83U10.1106/XBFG-FYFX-9TW9-M83U ↗
22. 10.1021/bm010163v10.1021/bm010163v ↗
23. Baichwal, A. R.; Staniforth, J. N. Sustained Release Excipient and Tablet Formulation. U.S. Patent. No. 5,128,143, 1992.
24. 10.1517/17425247.2.3.58710.1517/17425247.2.3.587 ↗
25. 10.1021/acsbiomaterials.8b0041510.1021/acsbiomaterials.8b00415 ↗
26. Badwan, A. A.; Al-Remawi, M.; Salem, M. Universal Controlled-Release Composition Comprising Chitosan. European Patent EP1512394, 2008.
27. 10.1016/j.ijbiomac.2013.12.01710.1016/j.ijbiomac.2013.12.017 ↗
28. 10.1016/j.ejpb.2007.06.00410.1016/j.ejpb.2007.06.004 ↗
29. 10.3390/md805171610.3390/md8051716 ↗
30. 10.3109/10837450.2011.62096810.3109/10837450.2011.620968 ↗
31. Al Remawi M. · J. Excipients Food Chem. · 2013 · 4 · 48
32. Al-Akayleh F. · J. Excipients Food Chem. · 2014 · 5 · 140
33. 10.1016/S0378-5173(01)00720-710.1016/S0378-5173(01)00720-7 ↗
34. Abdul Rahim S. A. · 2016 · 67
35. 10.1080/10717544.2017.139930510.1080/10717544.2017.1399305 ↗
36. 10.3390/polym1003026710.3390/polym10030267 ↗
37. 10.1016/j.carbpol.2017.11.02310.1016/j.carbpol.2017.11.023 ↗
38. Dumitriu, S.; Chornet, E.; Vidal, P. Polyionic Insoluble Hydrogels Comprising Xanthan and Chitosan. U.S. Patent No. 5,620,706, 1997.
39. 10.1016/j.powtec.2016.05.01910.1016/j.powtec.2016.05.019 ↗
40. Lexicomp Online. Metoprolol: Drug information. Wolters Kluwer Clinical Drug Information Inc: Hudson, OH, 2016; https://online.lexi.com/ (accessed Sep 12, 2017).
41. 10.1093/nar/gkx103710.1093/nar/gkx1037 ↗
42. 10.1002/jcc.2082010.1002/jcc.20820 ↗
43. Case, D. A.; Darden, T. A.; Cheatham, T. E.; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Walker, R. C.; Zhang, W.; Merz, K. M.; Roberts, B.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Kolossváry, I.; Wong, K. F.; Paesani, F.; Vanicek, J.; Liu, J.; Wu, X.; Brozell, S. R.; Steinbrecher, T.; Gohlke, H.; Cai, Q.; Ye, X.; Wang, J.; Hsieh, M.J.; Cui, G.; Roe, D. R.; Mathews, D. H.; Seetin, M. G.; Sagui, C.; Babin, V.; Luchko, T.; Gusarov, S.; Kovalenko, A.; Kollman, P. A. AMBER 11; University of California, San Francisco, 2010.
44. Woods Group (2005–2017). Carbohydrate Builder. In GLYCAM web; Complex Carbohydrate Research Center, University of Georgia: Athens, GA; http://glycam.org (accessed May 20, 2017).
45. 10.1063/1.46439710.1063/1.464397 ↗
46. 10.1016/0263-7855(96)00018-510.1016/0263-7855(96)00018-5 ↗
47. 10.1126/science.776182910.1126/science.7761829 ↗
48. ICH Harmonised Tripartite Guideline. Validation of analytical procedures: text and methodology Q2 (R1); International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2005; https://www.ich.org/products/guidelines.html (accessed Nov 23, 2017).
49. Food and Drug Administration (FDA). Draft Guidance on Metoprolol Succinate; 2008; https://www.fda.gov/downloads/Drugs/···/Guidances/UCM088687.pdf (accessed Jan 14, 2018).
50. 10.3390/md1510029810.3390/md15100298 ↗
51. 10.1016/j.carbpol.2018.09.03210.1016/j.carbpol.2018.09.032 ↗
52. 10.1002/app.2430610.1002/app.24306 ↗
53. 10.1016/S0008-6215(99)00263-310.1016/S0008-6215(99)00263-3 ↗
54. 10.5402/2012/73062410.5402/2012/730624 ↗
55. 10.1016/j.jddst.2017.09.00110.1016/j.jddst.2017.09.001 ↗
56. 10.1208/s12249-008-9174-110.1208/s12249-008-9174-1 ↗
57. Sahu S. K. · World J. Pharm. Pharm. Sci. · 2018 · 7 · 1228
58. Ghori M. U. · Am. J. Pharmacol. Sci. · 2015 · 3 · 103
59. 10.1080/1071754050031335610.1080/10717540500313356 ↗
60. 10.3109/0363904940905022510.3109/03639049409050225 ↗
61. Food and Drug Administration (FDA) · 1997
62. 10.1016/j.ijpharm.2013.04.05210.1016/j.ijpharm.2013.04.052 ↗
63. 10.1016/j.carbpol.2018.02.01110.1016/j.carbpol.2018.02.011 ↗
64. 10.1016/j.ijpharm.2014.09.05710.1016/j.ijpharm.2014.09.057 ↗
65. 10.1109/IGARSS.2004.136974310.1109/IGARSS.2004.1369743 ↗
66. 10.3109/10717544.2014.90897910.3109/10717544.2014.908979 ↗
67. 10.1016/j.saa.2017.12.05510.1016/j.saa.2017.12.055 ↗
68. 10.1021/acs.analchem.7b0415110.1021/acs.analchem.7b04151 ↗
69. 10.1016/j.ajps.2017.07.01010.1016/j.ajps.2017.07.010 ↗
70. 10.1016/j.ijpharm.2010.12.03010.1016/j.ijpharm.2010.12.030 ↗
71. 10.1016/j.ijpharm.2015.07.04510.1016/j.ijpharm.2015.07.045 ↗
72. 10.1080/0363904060101552110.1080/03639040601015521 ↗
73. 10.1016/j.ajps.2014.08.00210.1016/j.ajps.2014.08.002 ↗
74. 10.1021/acs.molpharmaceut.5b0095510.1021/acs.molpharmaceut.5b00955 ↗
75. 10.1016/j.ejpb.2014.02.00810.1016/j.ejpb.2014.02.008 ↗
76. 10.1208/s12249-015-0358-110.1208/s12249-015-0358-1 ↗